Low-level viremia associated with the use of TaqMan assay.
Poor correlation has been reported between the Roche Cobas AmpliPrep/Cobas (TaqMan) HIV-1 TaqMan assay and the Roche Cobas Amplicor HIV-1 Monitor version 1.5 Amplicor assay. We report 8 patients who experienced unexplained detectable viremia, despite exemplary medication adherence, following a change in viral quantification assay from Amplicor to TaqMan in January 2008. All patients were found to have undetectable HIV RNA by branched DNA (bDNA) assay.
Szabo
Susan
S
HIV Community Program, Christiana Care Health System, Wilmington, DE 19899, USA. sszabo@christianacare.org
Moffett
Lee E
LE
Cantwell-McNelis
Kelly
K
James
Christopher W
CW
Joseph
Abraham
A
D000328:Adult; D044966:Anti-Retroviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D021121:Branched DNA Signal Amplification Assay; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000302:isolation & purification* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods*; D012367:RNA, Viral / Q000097:blood; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D019914:Taq Polymerase; D019562:Viral Load / Q000502:physiology*; D014766:Viremia / Q000188:drug therapy / Q000821:virology*
D044966:Anti-Retroviral Agents; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic; D019914:Taq Polymerase